Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 238

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 238
---
000 |     |              |    * |
| Directors and senior management as a group (5 persons) (9) |     |                   |  57,521,640 |     |              |    * |

__________________

| * | Less than one percent of the outstanding Ordinary Shares. |

| ** | Excludes certain securities subject to a beneficial ownership blocker. See notes (1) to (3) below. |

| (1) | Based primarily on the Schedule 13G filed by Bigger Capital Fund, LP, Bigger Capital Fund GP, LLC, District                                 
 2 Capital Fund LP, District 2 Capital LP, District 2 GP LLC, District 2 Holdings LLC and Michael Bigger with the SEC on November 12, 2024,  
 and our information and belief. Consists of (i) warrants to purchase an aggregate of 843,460,000 Ordinary Shares (in the form of Depositary 
 Shares) beneficially owned by Bigger Capital Fund, LP and (ii) (x) warrants to purchase an aggregate of 878,570,000 Ordinary Shares (in     
 the form of Depositary Shares) and (y) 40,320,000 Ordinary Shares (in the form of Depositary Shares) beneficially owned by beneficially     
 owned by District 2 Capital Fund LP. Bigger Capital Fund GP, LLC is the general partner of, and may be deemed to beneficially own the       
 securities owned by, Bigger Capital Fund, LP. Each of (i) District 2 Capital LP, as the investment manager of District 2 Capital Fund       
 LP, (ii) District 2 GP LLC, as the general partner of District 2 Capital Fund LP, and (iii) District 2 Holdings LLC, as the managing member 
 of District 2 GP LLC, may be deemed to beneficially own securities owned by District 2 Capital Fund LP. Mr. Bigger is the managing member   
 of Bigger Capital Fund GP, LLC and is the managing member of District 2 Holdings LLC and may be deemed to beneficially own the securities   
 held by Bigger Capital Fund, LP and District 2 Capital Fund LP. The percentage in this table reflects that the reporting persons may not    
 exercise the warrants to the extent such exercise would cause the reporting persons to beneficially own a number of Ordinary Shares that    
 would exceed 9.99% of our then outstanding share capital following such exercise. The principal business address of the reporting person    
 is 117